Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INCB099280

Small molecule · Inhibitor of programmed death-ligand 1 (CD274) · developed by Incyte

Phase 2 Most advanced trial (none active)
INCY Developer
1 Registered trials

What is INCB099280?

INCB099280 is an orally bioavailable small molecule that binds PD-L1 expressed on tumor cells, blocking its interaction with PD-1 and reversing T-cell inactivation. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
programmed death-ligand 1 (CD274)
Mechanism
Inhibitor of programmed death-ligand 1 (CD274)
Pathways
PD-1/PD-L1 signaling, T-cell activation, anti-tumor cytotoxic T-lymphocyte response
Therapy area
Oncology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05888844 Phase 2 Cutaneous Squamous Cell Carcinoma Terminated INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on CD274

More from Incyte

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind INCB099280

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.